Terapi Berbasis Sel Punca untuk Stroke Iskemik Kronik dengan Mesenchymal Stem Cell Alogenik Intravena

  • Feby Aulia Hasanah Universitas Lampung
  • Nirvana Sabila Nuban Universitas Lampung
Keywords: alogenik, mesenchymal stem sell, intravena, stroke iskemik kronik, terapi sel punca

Abstract

Mesenchymal Stem Cell atau MSC merupakan sel punca dari sumsum tulang yang bersifat multipotensi untuk berproliferasi menjadi sel-sel neuron dewasa. MSC memiliki karakteristik unik berupa kemampuan neuroprotektif dalam menurunkan inflamasi sehingga dapat menghindari lingkungan toxic yang menyebabkan kematian sel NSC dan dapat mensekresikan berbagai faktor neurotropik untuk mendukung perkembangan sel NSC pada pasien stroke iskemik kronik. Tujuan literature review ini yaitu untuk mengetahui efek terapi terobosan baru berbasis sel punca MSC Alogenik Intravena pada stroke iskemik kronik. Metode yang digunakan adalah metode literature review dari 30 artikel PubMed NCBI, Google Schoolar, dan Elsevier dari tahun 2002 hingga 2019 dan hanya diambil sekitar 19 artikel terpilih. Dari beberapa penelitian yang dilakukan didapatkan hasil uji klinis terkini tahap I dan II bahwa terapi MSC dapat meningkatkan kemampuan fungsional secara positif pada pasien stroke iskemik kronik secara signifikan dengan rata-rata senilai 10 persen dengan minimal efek samping pada rute intravena yang bersumber dari alogenik sumsum tulang. MSC merangsang efek SDF-1/CXCR4 sehingga MSC alogenik dapat memodulasi respon inflamasi dan mampu berperan sebagai efek tropic dan neuroprotektif melalui stimulasi neurogenesis, oligodendrogenesis, astrogenesis, remielinisasi, plastisitas aksonal dan angiogenesis. Karena terapi untuk stroke iskemik kronik masih sangat terbatas hingga saat ini, MSC alogenik dapat menjadi kandidat terapi karena pengembangannya yang mudah dan efektif.

References

Apriandra R. 2019. Infodatin: stroke don’t be the one. Kemenkes RI.

Bang OY, Lee JS, Lee PH, Lee G. 2005. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 57:874–882.

Bhasin A, Srivastava MV, Kumaran SS, Mohanty S, Bhatia R, Bose S, et al. 2011. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra.1:93–104.

Boese AC, Le Q-SE, Pham D, Hamblin MH, Lee J-P. 2018. Neural stem cell therapy for subacute and chronic ischemic stroke. Stem Cell Res Ther. 9(1) :154

Castillo-Melendez M, Yawno T, Jenkin G, Miller SM. 2013. Stem cell therapy to protect and repair the developingbrain : a review of mechanisms of action of cord blood and amnion epithelial derived cell. Front Neurosci. 7:194

Dabrowska S, Andrzejewska A, Lukomska B, Janowski M. 2019. A Review: Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles. Journal of Neuroinflammation. 16:178

Devine SM. 2002. Mesenchymal stem cells: will they have a role in the clinic? J Cell Biochem Suppl. 38:73–79.

El Bassit G, Patel RS, Carter G, Shibu V, Patel AA, Song S, et al. 2017. MALAT1 in human adipose stem cells modulates survival and alternative splicing of PKCδII in HT22 cells. Endocrinology. 158(1):183–95.

Ferrarello F, Baccini M, Rinaldi LA, Cavallini MC, Mossello E, Masotti G, et al. 2011. Efficacy of physiotherapy interventions late after stroke: a meta-analysis.J Neurol Neurosurg Psychiatry. 82:136–143.

Figueroa FE, Carrión F, Villanueva S, Khoury M. 2012. Mesenchymal stem cell treatment for autoimmune diseases: a critical review. Biol Res. 45:269–277.

Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, et al. 2017. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16:360–368.

Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, et al. 2011. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 134(pt 6):1790–1807.

Hsuan YC, Lin CH, Chang CP, Lin MT. 2016. Mesenchymal stem cell-based treatments for stroke, neural trauma, and heat stroke. Brain Behav. Aug 3; 6(10): e00526.

Kemenkes RI. 2018. Kebijakan dan pengendalian stroke di Indonesia.

Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. 2012. Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 7:e47559 11

Levy ML, et al. 2019. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. AHA Journals. 50(10): 2835-41

Lin SS, Zhu B, Guo Z-K, Huang G-Z, Wang Z, Chen J, et al. 2014. Bone marrow mesenchymal stem cell-derived microvesicles protect rat pheochromocytoma PC12 cells from glutamate-induced injury via a PI3K/ Akt dependent pathway. Neurochem Res. 39(5):922–31.

Marei HE, Hasan A, Rizzi R, Althani A, Afifi N, Cenciarelli C, Caceci T, Shuaib A. 2018. Potential of Stem Cell-Based Therapy for Ischemic Stroke. Front Neurol. 6(9):34.

Moradi F, Haji Ghasem Kashani M, Ghorbanian MT, Lashkarbolouki T. 2012. Spontaneous expression of neurotrophic factors and TH, Nurr1, Nestin genes in long-term culture of bone marrow mesenchymal stem cells. Cell J. 13:243–250.

Savitz SI, Yavagal D, Rappard G, Likosky W, Rutledge N, Graffagnino C, et al. 2019. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). Circulation. 139:192–205.

Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC. 2013. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes. 6:543–549.

Steinberg GK, et al. 2016. Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke. 47(7): 1817–24

Tsang KS, Ng CPS, Zhu XL, Wong GKC, Lu G, Ahuja AT, et al. 2017. Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World J Stem Cells. 9:133–143.

Ullah I, Subbarao RB, Rho GJ. 2015. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 35(2):e00191.

Vertelov G, Kharazi L, Muralidhar MG, Sanati G, Tankovich T, Kharazi A. 2013. High targeted migration of human mesenchymal stem cells grown in hypoxia is associated with enhanced activation of RhoA. Stem Cell Res Ther. 4:5. 12

Vu Q, Xie K, Eckert M, Zhao W, Cramer SC. 2014. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology. 82:1277–86.

Wechsler LR, Bates D, Stroemer P, Zwilling YSA, Aizman I. 2018. Cell Therapy for Chronic Stroke. AHA Journals. 5(49): 1066-74.

Williams AR, Hare JM. 2011. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 109:923–940.

Wittenauer R, Smith L. 2012. Ischaemic and Haemorrhagic Stroke. WHO. 6: 3-9.

Zhang ZG, Chopp M. 2009. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 8:491–500.

Published
2021-01-22
How to Cite
Hasanah, F., & Nuban, N. (2021). Terapi Berbasis Sel Punca untuk Stroke Iskemik Kronik dengan Mesenchymal Stem Cell Alogenik Intravena. Jurnal Penelitian Perawat Profesional, 3(1), 99-106. https://doi.org/10.37287/jppp.v3i1.338

Most read articles by the same author(s)